imatge_slider_01.jpeg

VCN Biosciences:

Highly selective viruses specifically designed
to treat refractory tumors
Slide1

VCN Biosciences:

The company developing the next generation
of oncolytic adenovirus
Slide2
Our oncolytic adenoviruses are designed
to obtain clinical activity by systemic administration

VCN Biosciences SL, a wholly-owned subsidiary of Synthetic Biologics Inc. (NYSE American: SYN), is focused on the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for VCN-01.

 

News

Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors

-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, andidentify recommended Phase 2 dose (RP2D)-
-Publication further supports the development of Synthetic Biologics’ novel oncolytic adenovirus (OV)platform-

Read more ...
Synthetic Biologics Announces VCN Biosciences’ VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

Follows recent announcement of planned acquisition of VCN Biosciences by Synthetic Biologics.

Read more ...
VCN Biosciences Announces Publication in Peer-Reviewed Journal of Immunotherapy of Cancer on Clinical Data obtained with VCN-01 after intratumorally administration in patients with Pancreatic Cancer

VCN Biosciences Announces Publication in Peer-Reviewed Journal of Immunotherapy of Cancer on Clinical Data obtained with VCN-01 after intratumorally administration in patients with Pancreatic Cancer

Read more ...
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid TumorsLead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trialsDesigned for systemic delivery, high selectivity, and enhanced tumor accessVCN-01 granted Orphan Drug Designation in Pancreatic Cancer by the EMASynthetic Biologics and VCN Biosciences to host a conference call today, December 14th, at 10:00 a.m. Eastern Time

For Immediate Release

Read more ...